Akeso (HKSE:09926) Debt-to-Equity : 0.64 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Akeso Debt-to-Equity?

Akeso's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$443 Mil. Akeso's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$2,828 Mil. Akeso's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$5,132 Mil. Akeso's debt to equity for the quarter that ended in Dec. 2023 was 0.64.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Akeso's Debt-to-Equity or its related term are showing as below:

HKSE:09926' s Debt-to-Equity Range Over the Past 10 Years
Min: -23.94 Med: 0.21 Max: 0.71
Current: 0.64

During the past 6 years, the highest Debt-to-Equity Ratio of Akeso was 0.71. The lowest was -23.94. And the median was 0.21.

HKSE:09926's Debt-to-Equity is ranked worse than
79.52% of 1074 companies
in the Biotechnology industry
Industry Median: 0.145 vs HKSE:09926: 0.64

Akeso Debt-to-Equity Historical Data

The historical data trend for Akeso's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Debt-to-Equity Chart

Akeso Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-23.94

0.06

0.27

0.71

0.64

Akeso Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial						0.27	0.51	0.71	0.49	0.64

Competitive Comparison of Akeso's Debt-to-Equity

For the Biotechnology subindustry, Akeso's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akeso's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Akeso's Debt-to-Equity falls into.

Akeso Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Akeso's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(443.01	+	2828.375)	/	5132.381
	=	0.64

Akeso's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(443.01	+	2828.375)	/	5132.381
	=	0.64

Akeso (HKSE:09926) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Akeso Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Akeso's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso (HKSE:09926) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

AKESF:USA 4RY:Germany

Address

6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437

Website

https://www.akesobio.com

Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Akeso (HKSE:09926) Headlines

No Headlines